A Study to Determine the Safety and Effectiveness of the Investigational Cellular Therapy GCAR1 in a Patient With Alveolar Soft Part Sarcoma
Opening soon Early Phase 1 NCT07104682
Run by University of Calgary · for All ages · Men
What this study is about
A single patient study to determine whether GCAR1 is safe and effective for refractory, progressive metastatic alveolar soft part sarcoma (ASPS).
Who can join (things the study team will check)
✅ You may be able to join if…
- The patient must have relapsed ASPS that is in the opinion of the treating physician not resectable, or that resection would be associated with significant morbidity.
- The patient must provide informed consent.
- The only other eligibility criteria is adequate organ function, defined as creatinine clearance >30 ml/min and LVEF >45%.
🚫 You may not be able to join if…
- Any active uncontrolled infection
- Any anti-cancer therapy within 21 calendar days prior to the first dose of lymphodepleting chemotherapy
Where this trial is running
- University of Calgary, Calgary, Canada
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.